- Home
- COGT vs MSIF Comparison
COGT vs MSIF Comparison
Compare COGT & MSIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- MSIF
- Stock Information
- Founded
- COGT 2014
- MSIF 2011
- Country
- COGT United States
- MSIF United States
- Employees
- COGT N/A
- MSIF N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- MSIF
- Sector
- COGT Health Care
- MSIF
- Exchange
- COGT Nasdaq
- MSIF NYSE
- Market Cap
- COGT 806.1M
- MSIF 795.9M
- IPO Year
- COGT 2018
- MSIF N/A
- Fundamental
- Price
- COGT $7.41
- MSIF $16.31
- Analyst Decision
- COGT Buy
- MSIF Buy
- Analyst Count
- COGT 6
- MSIF 5
- Target Price
- COGT $15.20
- MSIF $18.50
- AVG Volume (30 Days)
- COGT 2.4M
- MSIF 106.5K
- Earning Date
- COGT 08-05-2025
- MSIF 05-12-2025
- Dividend Yield
- COGT N/A
- MSIF 8.88%
- EPS Growth
- COGT N/A
- MSIF N/A
- EPS
- COGT N/A
- MSIF 1.50
- Revenue
- COGT N/A
- MSIF $134,105,000.00
- Revenue This Year
- COGT N/A
- MSIF $9.98
- Revenue Next Year
- COGT N/A
- MSIF $10.94
- P/E Ratio
- COGT N/A
- MSIF $10.90
- Revenue Growth
- COGT N/A
- MSIF N/A
- 52 Week Low
- COGT $3.72
- MSIF $14.01
- 52 Week High
- COGT $12.61
- MSIF $18.10
- Technical
- Relative Strength Index (RSI)
- COGT 64.24
- MSIF N/A
- Support Level
- COGT $7.07
- MSIF N/A
- Resistance Level
- COGT $7.50
- MSIF N/A
- Average True Range (ATR)
- COGT 0.43
- MSIF 0.00
- MACD
- COGT -0.06
- MSIF 0.00
- Stochastic Oscillator
- COGT 55.94
- MSIF 0.00
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About MSIF MSC INCOME FUND INC
MSC Income Fund Inc is a non-diversified closed-end management investment company. The investment objective is to generate current income through debt and equity investments and the secondary objective is to generate long-term capital appreciation through such investments. The company invests in senior secured term loans, second lien loans, and mezzanine debt and selected equity investments issued by lower middle-market and middle-market companies.